viewCentrexion Therapeutics Corp

IPO Roundup: Non-opioid pain treatment developer Centrexion Therapeutics set to IPO

The Massachusetts-based biopharma is led by former Pfizer CEO Jeffrey B. Kindler

IPO and gold coins
Two blank-check companies and two fintech companies plan to price shares as well

A total of six companies will price their shares this week, including two blank-check companies, two biopharmas and two fintech-related companies.


Vapotherm Inc (NYSE:VAPO) will be one of the first initial public offerings of the week. The New Hampshire-based company develops non-invasive breathing aids for those with respiratory distress. The company was founded about 25 years ago and reported $41 million in revenue for the year as of September 2018. Vapotherm plans to offer 4 million shares priced between $14 and $16, raising up to $64 million.


Weidai Ltd (NYSE:WEI) is one of two fintech IPOs on deck for this week. The China-based company operates a platform that provides auto-secured loans for small businesses in China. Founded in 2011, the company reported $565 million in revenue for the year as of June 2018. Weidai plans to offer 4.5 million shares priced between $9 and $11, raising up to $49.5 million.

READ: OPKO Health sees prescriptions for Rayaldee triple in third quarter

Centrexion Therapeutics Corp (NASDAQ:CNTX) is the first biopharma set to price its shares this week. The Massachusetts-based company specializes in developing non-opioid pain treatments. The biopharma is led by former Pfizer Inc (NYSE:PFE) CEO Jeffrey B. Kindler. Centrexion Therapeutics plans to offer 5 million shares priced between $14 and $16, raising up to $80 million.


Taiwan Liposome Company Ltd (NASDAQ:TLC) is the second biopharma of the week gearing up to go public. The clinical-stage specialty pharmaceutical company develops nanomedicines for pain and eye diseases. The Taiwan-based company plans to offer 5 million ADS shares priced at $5.80, lower than its initial offer of 4.7 million shares priced at $7.46. The company could raise as much as $29 million.

Fintech Acquisition Corp III (NASDAQ:FTACU) will price its shares at the end of the week. The blank-check company was formed to acquire fintech businesses. The Philadelphia-based company was formed by the management of Bancorp, which provides private label banking and technology services. The company will offer 27.5 million shares priced at $10, raising up to $275 million.

AMCI Acquisition Corp (NASDAQ:AMCIU) is the second blank-check company pricing shares this week. The special acquisition company said it will focus on the global natural resources sector. AMCI will offer 20 million shares priced at $10 each. The company could raise as much as $200 million in its IPO.


Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee


Quick facts: Centrexion Therapeutics Corp

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Minera Alamos announces 14-million-dollar deal with Osisko Gold Royalties to...

Minera Alamos (CVE: MAI) President Doug Ramshaw joined Steve Darling from Proactive Vancouver on Skype with details about a deal they have signed with Osisko Gold Royalties to help fund construction on their Santana project in Mexico. Ramshaw telling Proactive how the deal will work and the...

2 days, 10 hours ago

3 min read